Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Relationship between Protein Intake and Source on Factors Associated with Glycemic Control in Individuals with Prediabetes and Type 2 Diabetes.
Akhavan NS, Pourafshar S, Johnson SA, Foley EM, George KS, Munoz J, Siebert S, Clark EA, Basiri R, Hickner RC, Navaei N, Levenson CW, Panton LB, Daggy BP, Arjmandi BH. Akhavan NS, et al. Among authors: siebert s. Nutrients. 2020 Jul 8;12(7):2031. doi: 10.3390/nu12072031. Nutrients. 2020. PMID: 32650580 Free PMC article.
The Short-Term Effect of Prunes in Improving Bone in Men.
George KS, Munoz J, Ormsbee LT, Akhavan NS, Foley EM, Siebert SC, Kim JS, Hickner RC, Arjmandi BH. George KS, et al. Among authors: siebert sc. Nutrients. 2022 Jan 10;14(2):276. doi: 10.3390/nu14020276. Nutrients. 2022. PMID: 35057457 Free PMC article. Clinical Trial.
Is soy protein effective in reducing cholesterol and improving bone health?
George KS , Muñoz J , Akhavan NS , Foley EM , Siebert SC , Tenenbaum G , Khalil DA , Chai SC , Arjmandi BH . George KS , et al. Among authors: siebert sc. Food Funct. 2020 Jan 29;11(1):544-551. doi: 10.1039/c9fo01081e. Food Funct. 2020. PMID: 31848551 Clinical Trial.
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Among authors: siebert s. Lancet Rheumatol. 2024 May 8:S2665-9913(24)00065-1. doi: 10.1016/S2665-9913(24)00065-1. Online ahead of print. Lancet Rheumatol. 2024. PMID: 38734019 Free article.
347 results